Monica D. Mead, MD The continued emergence of data for BTK inhibitors, including ibrutinib (Imbruvica), zanubrutinib (Brukinsa), and pirtobrutinib (Jaypirca), have shifted the role of these agents in the treatment paradigm for patients with mantle cell lymphoma (MCL), including key findings the phase 3 TRIANGLE trial (NCT02858258), the phase 1/2 BGB-3111-AU-003 trial (NCT02343120), and the […]
Bradley McGregor, MD Treatment with the combination of cabozantinib (Cabometyx), nivolumab (Opdivo), and ipilimumab (Yervoy) elicited an objective response rate of 18% (80% CI, 10%-28%) with a disease control rate of 76% at a median follow-up of 10.4 months for patients with renal cell carcinoma with variant histologies (RCCvh). Findings come from a multi-institutional, prospective, […]
John A. Scarlett, MD The FDA has accepted a new drug application (NDA) seeking the approval of imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndrome (MDS).1 The NDA is supported by findings from the phase 3 IMerge trial (NCT02598661), which demonstrated that patients treated with imetelstat (n = 118) experienced […]
“Factors associated with withdrawal of consent should be considered when designing trials and should be further studied to learn how they can be favorably modified,” according to the authors of a study published in JAMA Oncology. Consent withdrawal rate across 58 clinical trials was less than 10% overall—an observation that remained consistent over time—and the […]
Cancer Research UK and Blood Cancer UK have awarded funding to a multidisciplinary team from the University of Oxford. These awards will help to advance the AI-based methods and predict the progression of myeloproliferative neoplasms (MPNs) more accurately. MPNs are a group of closely related disorders of the bone marrow affecting around 5000 people every […]
(Albany, USA) DelveInsight’s “ Eye Neoplasm Market Insights, Epidemiology, and Market Forecast-2032 ” report delivers an in-depth understanding of Eye Neoplasm, historical and forecasted epidemiology as well as the Eye Neoplasm market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Eye Neoplasm market report provides current treatment […]
The Department of Health (DOH) on Friday said tuberculosis is still one of the 10 leading causes of death in the Philippines despite the availability of treatment. Latest data from the Philippine Statistics Authority show that 15,689 out of 563,465 recorded deaths among Filipinos from January to November 2022 were categorized under respiratory tuberculosis. “From […]
Abstract Following the results of the IMpassion130 trial, an early access program (EAP) was opened in France, allowing patients with PD-L1-positive advanced triple negative breast cancer (aTNBC) to receive a combination of paclitaxel and atezolizumab as first line therapy. This EAP was later discontinued when the IMpassion131 trial read out with negative results. We performed […]
